Navigation Links
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Date:8/19/2007

arily the result

of non-cash charges related to share-based payments

-- Other expense second quarter 2007 were $2.6 million, compared to $0.3

million in the second quarter of 2006

* $2.3 million increase in other expenses is primarily the result of

non-cash charges related to the change in fair value of derivative

instruments

-- Second quarter 2007 revenues were $0.4 million, compared to the $5.2

million in the second quarter of 2006

-- Second quarter 2007 operating loss of $9.5 million, compared to an

operating loss of $3.4 million for the first quarter of 2006

-- Second quarter 2007 net loss was $12.1 million, or $0.43 per basic and

diluted share, compared to a net loss of $3.8 million, or $0.14 per

basic and diluted share for the second quarter of 2006

-- As of June 30, 2007, Emisphere has $8.9 million in cash and

investments. The Company is currently evaluating various financing

options to address its future cash needs that will enable the Company

to continue operations through the fourth quarter of 2007 and beyond.

Corporate and Product Developments

Emisphere has two Phase III products based on the compound salmon calcitonin in partnership with Novartis Pharma AG and its development partner, Nordic Bioscience:

-- One product relates to the prevention of osteoporosis and the other

product relates to the prevention of osteoarthritis

-- Osteoarthritis product has the potential to be the first disease-

modifying drug that halts progression of the illness rather than

treating symptoms

-- Both products use Emisphere's eligen(R) delivery technology to provide

salmon calcitonin for the first time as a convenient oral medication

Emisphere has three products in Phase II:

-- Development of recombinant human growth hormone ("rhGH") in

colla
'/>"/>

SOURCE Emisphere Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... MPMN and PlasticsToday.com, both leading news and ... today announced the launch of a new conference on ... the latest technological and regulatory developments in the use ... sustained growth despite broader economic difficulties, the value of ...
... N.J., Oct. 10, 2011 Cantel Medical Corp. (NYSE: ... quarter and fiscal year ended July 31, 2011 on Thursday, ... call to discuss the results at 11:00 AM ET.  Participating ... A. Krakauer, President and CEO; Seth R. Segel, Executive Vice ...
Cached Medicine Technology:MPMN and PlasticsToday Launch New Specialist Conference on Innovations in Medical Polymers 2Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2011 Results 2
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/23/2014)... Hospital (MGH) investigators may lead to greater availability and ... problem use of fecal material from healthy donors ... difficile ( C. difficile ) bacteria. In ... Clinical Infectious Diseases , the researchers report that use ... patients was as successful in curing recurrent C. ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... Older African American women who have experienced high levels ... to suffer worse physical and mental health than their ... of the Journal of Women,s Health . , ... health issues such as depression and anxiety, and more ...
... Following a review by The Lancet of the ... of Cardiology has reaffirmed its advice about the risks of ... , is increased "up to four-fold" by long-haul flight. , ... flying is associated with an increase in deep venous thrombosis, ...
... flights in 9 minutes, 31 secondsCHICAGO, Feb. 23 Over ... Hancock stair climb event on Sunday, February 22. They did ... lung disease, the third leading cause of death and disability ... raise more than $1 million to benefit Respiratory Health Association ...
... VANCOUVER, Feb. 24 /PRNewswire-FirstCall/ - CRH Medical Corporation announced ... Hemorrhoid banding technology has been adopted by more than ... Company since June 2008. The Company believes this provides ... but also confirmation of the consistency of its training ...
... new survey from global market research firm Synovate shows that less than ... months. Of those, only 10% received it at a pharmacy and just ... ... February 24, 2009 -- According to a new survey by leading market ...
... Online-Only Event Brings Together Leading Cardiovascular ExpertsLAS ... Inc. (NMT), an award-winning company engaged in ... today announced that the Company will be ... medical assessment and communications products at CardioCareLive, ...
Cached Medicine News:Health News:Triple threat to health 2Health News:ESC reaffirms advice on cardiovascular risks associated with long-haul flights 2Health News:Over 4,000 Hustle Up the Hancock to Fight Lung Disease 2Health News:CRH provides Partnership Program update 2Health News:New survey: Flu Shot Still not Catching on, Especially at Retail Clinics 2Health News:Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference 2Health News:Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference 3
... Mesh Self-Forming Plug is a mesh plug ... well as primary inguinal hernias and femoralhernias. ... defect and fills it completely. Premilene Mesh ... of the established Premilene Mesh. The plug ...
... The Celsius Control System provides ... can safely,and rapidly lower patient ... target temperature and,rewarm patients to ... System consists of an endovascular,catheter, ...
... , it maximizes use by allowing ... it, while the third lamp is ... care in mind, it includes universal ... An excellent choice for hospital operating ...
... Perfectly balanced, the patented Orion incorporates ... that illuminates brilliantly. The fully adjustable ... designed to sit low on the brow, ... vision. Two clips on the headband ...
Medicine Products: